Credihealth

credihealth.com

Credihealth is an online solution to all your healthcare needs. Our team of medical experts are there for you in every step of the way: from finding the right doctor and hospital to any kind of assistance. We educate and empower families to ensure that right healthcare decisions are made. With personalized advice, we are changing the face of healthcare delivery across India.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

TETRA BIO-PHARMA GETS ORPHAN DRUG STATUS FOR CBD DRUG

Greenmarketreport | April 22, 2020

news image

Tetra Bio-Pharma Inc. (OTCQB:TBPMF) announced its Orphan Drug development strategy and provided a management update. The company said it is focusing on generating intellectual property including use, manufacturing, and innovative molecule protection. Tetra said it received a U.S. Food and Drug Administration (FDA) Orphan Drug Designation for secondary cannabidiol (CBD) formulation of its cannabinoid topical drug PPP004 in the treatment of epidermolysis bullosa. “Each ODD application is dri...

Read More

Pharmacy Market

VINCERX PHARMA ANNOUNCES FDA CLEARANCE OF IND FOR VIP943

Globenewswire | August 23, 2023

news image

Vincerx Pharma, Inc. a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today reported that it has received clearance for its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) to initiate a Phase 1 clinical trial for VIP943. Vincerx expects to enroll the first patient in the study early in the fourth quarter of 2023. "The IND clearance by the FDA is...

Read More

Pharmacy Market

THE MCQUADE CENTER FOR STRATEGIC RESEARCH AND DEVELOPMENT AND MINDSET PHARMA COLLABORATE TO DEVELOP PSYCHEDELIC MEDICINES

McQuade | January 06, 2022

news image

The McQuade Center for Strategic Research and Development, LLC, a member of the global Otsuka family of pharmaceutical companies, and Mindset Pharma Inc. announce a collaboration that will support the development of psychedelic medicines. MSRD has made a strategic investment to support the discovery and development of novel chemical entity assets of Mindset, a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurol...

Read More

Research

CORIUM ANNOUNCES PUBLICATION OF ADLARITY® CLINICAL TRIAL DATA: DRUG EXPOSURE EQUIVALENT TO ORAL DONEPEZIL WITH FAVORABLE GI SIDE EFFECT PROFILE

Corium, Inc. | September 20, 2022

news image

Corium, Inc., a fully-integrated biopharmaceutical company leading the development and commercialization of novel central nervous system therapies, announced publication of its phase 1 healthy volunteer study results for ADLARITY in the peer-reviewed Journal of Alzheimer's Disease. The article, "Comparison of Steady-State Pharmacokinetics of Donepezil Transdermal Delivery System with Oral Donepezil," reports that Corium's novel once-weekly Alzheimer's dementia treatment del...

Read More
news image

TETRA BIO-PHARMA GETS ORPHAN DRUG STATUS FOR CBD DRUG

Greenmarketreport | April 22, 2020

Tetra Bio-Pharma Inc. (OTCQB:TBPMF) announced its Orphan Drug development strategy and provided a management update. The company said it is focusing on generating intellectual property including use, manufacturing, and innovative molecule protection. Tetra said it received a U.S. Food and Drug Administration (FDA) Orphan Drug Designation for secondary cannabidiol (CBD) formulation of its cannabinoid topical drug PPP004 in the treatment of epidermolysis bullosa. “Each ODD application is dri...

Read More
news image

Pharmacy Market

VINCERX PHARMA ANNOUNCES FDA CLEARANCE OF IND FOR VIP943

Globenewswire | August 23, 2023

Vincerx Pharma, Inc. a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today reported that it has received clearance for its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) to initiate a Phase 1 clinical trial for VIP943. Vincerx expects to enroll the first patient in the study early in the fourth quarter of 2023. "The IND clearance by the FDA is...

Read More
news image

Pharmacy Market

THE MCQUADE CENTER FOR STRATEGIC RESEARCH AND DEVELOPMENT AND MINDSET PHARMA COLLABORATE TO DEVELOP PSYCHEDELIC MEDICINES

McQuade | January 06, 2022

The McQuade Center for Strategic Research and Development, LLC, a member of the global Otsuka family of pharmaceutical companies, and Mindset Pharma Inc. announce a collaboration that will support the development of psychedelic medicines. MSRD has made a strategic investment to support the discovery and development of novel chemical entity assets of Mindset, a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurol...

Read More
news image

Research

CORIUM ANNOUNCES PUBLICATION OF ADLARITY® CLINICAL TRIAL DATA: DRUG EXPOSURE EQUIVALENT TO ORAL DONEPEZIL WITH FAVORABLE GI SIDE EFFECT PROFILE

Corium, Inc. | September 20, 2022

Corium, Inc., a fully-integrated biopharmaceutical company leading the development and commercialization of novel central nervous system therapies, announced publication of its phase 1 healthy volunteer study results for ADLARITY in the peer-reviewed Journal of Alzheimer's Disease. The article, "Comparison of Steady-State Pharmacokinetics of Donepezil Transdermal Delivery System with Oral Donepezil," reports that Corium's novel once-weekly Alzheimer's dementia treatment del...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us